Chemotherapy is currently the treatment of choice for patients with high-risk metastatic
breast cancer. Clinical response is determined after several cycles of chemotherapy by …

This study was conducted to determine the ability of 18F-FDG PET and conventional
imaging (CI) to predict the outcomes in breast cancer patients who have previously …

PURPOSE: To determine whether [18F]-fluorodeoxy-d-glucose ([18F]-FDG) positron
emission tomography (PET) can predict the pathologic response of primary and metastatic …

We investigated the role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography
(PET) in the early evaluation of response to chemotherapy in metastatic breast cancer …

Increasing numbers of patients with newly diagnosed breast cancer receive primary
systemic therapy followed by surgery. Histopathology provides an accurate assessment of …

Breast cancer prognosis is steadily improving due to early detection of primary cancer in
screening programs and revolutionizing treatment development. In the metastatic setting …

Changes in tumor metabolic activity have been shown to be an early indicator of treatment
effectiveness for breast cancer, mainly in the neoadjuvant setting. The histopathologic …

Purpose This study examines the use of [18F] fluorodeoxyglucose positron emission
tomography (FDG-PET) for the evaluation of the therapeutic response for patients treated …

PURPOSE: To address the role of positron emission tomography (PET) using [18F]
fluorodeoxyglucose (FDG) to monitor primary (neoadjuvant) chemotherapy in patients with …

Purpose: To evaluate the clinical value of positron emission tomography (PET) for
monitoring chemotherapy in metastatic breast cancer. Experimental Design: Twenty patients …